Avidity Biosciences Files Proxy Statement

TL;DR

AVDX proxy filing out - shareholders get the scoop on company biz.

AI Summary

Avidity Biosciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on November 20, 2025, related to soliciting materials under Rule 14a-12. The company, incorporated in Delaware with its principal office in San Diego, CA, is in the Pharmaceutical Preparations industry. This filing indicates ongoing corporate communications and potential shareholder engagement activities.

Why It Matters

Proxy statements are crucial for shareholders as they provide information about company matters being voted on, including executive compensation and board elections, impacting corporate governance.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain information that inherently increases risk for the company or its investors.

Key Players & Entities

• Avidity Biosciences, Inc. (company) — Registrant
• 20251120 (date) — Filing Date
• 3020 CALLAN ROAD (address) — Business and Mail Address
• SAN DIEGO (location) — City
• DE (location) — State of Incorporation
• 1231 (date) — Fiscal Year End
• 001-39321 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — hares of SpinCo Common Stock, par value $0.001 per share (" SpinCo Common Stock "), at
• $0.0001 — er 10 shares of common stock, par value $0.0001 per share, of the Company, with SpinCo

Filing Documents

• d782860ddefa14a.htm (DEFA14A) — 66KB
• 0001193125-25-289629.txt ( ) — 67KB

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding the proposed acquisition of Avidity and Avidity's related Spin-Off, the expected timetable for completing each of the proposed Transactions, the composition of the assets and liabilities to be held by SpinCo and Avidity following the Spin-Off, the management team for SpinCo and its cash balance, potential marketing approvals, new indications or labeling for Avidity's product candidates, Avidity's platform and preclinical assets, or potential future revenues from Avidity's product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are forward-looking statements. There can be no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time, or that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value. There can be no guarantee that the conditions to the closing of the Transactions will be satisfied on the expected timetable or at all or that the expected benefits or synergies from the Transactions will be achieved in the expected

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding the proposed acquisition of Avidity and Avidity's related spin-off, the expected timetable for completing each of the proposed Transactions, the composition of the assets and liabilities to be held by SpinCo and Avidity following the spin-off, the management team for SpinCo and its cash balance, potential marketing approvals, new indications or labeling for Avidity's product candidates, Avidity's platform and preclinical assets, or potential future revenues from Avidity's product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time, or that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value. There can be no guarantee that the conditions to the closing of the Transactions will be satisfied on the expected timetable or at all or that the expected benefits or synergies from the Transactions will be achieved in the expected ti

View Full Filing

View this DEFA14A filing on SEC EDGAR